← ANALYST RATINGS · TIPRANKS
Prestige Consumer Healthcare (PBH): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $72.00, the highest $72.00, the lowest $72.00. The average is +44.2% from the last price of $49.92.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - PharmaceuticalsxAI Grok-3 | TipRanks - xAI | $54.00 → $55.00+1.9% | Buy | +10.2% | Reiterated | 15.10.26on TipRanks Oct 14 23:06 | — | |
| AI DeepSeek Medical - PharmaceuticalsDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $55.00 → $56.00+1.8% | Buy | +12.2% | Reiterated | 15.10.26on TipRanks Oct 14 23:06 | — | |
| AI OpenAI Medical - PharmaceuticalsOpenAI 5.2 | TipRanks - OpenAI | $54.00 → $55.00+1.9% | Buy | +10.2% | Reiterated | 13.10.26on TipRanks Oct 12 23:06 | — | |
| AI Anthropic Medical - PharmaceuticalsAnthropic Opus-4.6 | TipRanks - Anthropic | $51.00 → $52.00+2.0% | Hold | +4.2% | Reiterated | 13.10.26on TipRanks Oct 12 23:06 | — | |
| AI Google Medical - PharmaceuticalsGemini 3-pro | TipRanks - Google | $55.00 → $56.00+1.8% | Buy | +12.2% | Reiterated | 13.10.26on TipRanks Oct 12 23:06 | — | |
| AI PerPlexity Medical - PharmaceuticalsPerPlexity SonarPro | TipRanks - PerPlexity | $50.00 → $51.00+2.0% | Buy | +2.2% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| Susan Anderson★★★★★★★★★★#576 · hits 45% · avg +16.7% | Canaccord Genuity | $72.00 | Buy | +44.2% | Reiterated | 06.08.26on TipRanks Aug 7 16:25 | +2.9%next day +0.2% · 5 days −6.9% | ↗ |
| Jon Andersen★★★★★★★★★★#11312 · hits 50% · avg −3.7% | William Blair | — | Buy | — | Reiterated | 06.08.26on TipRanks 08:55 | +2.9%next day +0.2% · 5 days −6.9% | ↗ |
| Rupesh Parikh★★★★★★★★★★#487 · hits 62% · avg +11.8% | Oppenheimer | — | Hold | — | Downgrade | 14.05.26on TipRanks 05:40 | −12.1%next day +3.0% · 5 days +5.7% | ↗ |
| Paul Treiber★★★★★★★★★★#869 · hits 56% · avg +9.5% | RBC Capital | $92.95 → $90.84−2.3% | Buy | +82.0% | Reiterated | 19.03.26on TipRanks Mar 20 07:30 | −0.9%next day +3.0% · 5 days +2.5% | ↗ |
| Keith Devas★★★★★★★★★★#11126 · hits 14% · avg −11.8% | Jefferies | $70.00 → $66.00−5.7% | Hold | +32.2% | Reiterated | 30.01.26on TipRanks 12:55 | +1.2%next day +1.0% · 5 days +3.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Prestige Consumer Healthcare
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $72.00 at a price of $45.87 (+57.0%); now: $72.00 at $49.92 (+44.2%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 0 | 0 |
| Buy | 5 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q2 2027, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $1.07 (from $1.05 to $1.08). Last quarter: $0.98.
Sales
Next quarter’s sales estimate — $329M (from $329M to $330M). Last quarter: $266M.
Best top-analyst consensus in the sector · Healthcare
About Prestige Consumer Healthcare
- CEO: Ronald Lombardi
- Employees: 890
- 660 White Plains Road, Tarrytown, NY, 10591, US
- www.prestigebrands.com
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.
Data from the stock’s TipRanks forecast page, read 236 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗